Premium
Patient demographics and management landscape of metastatic colorectal cancer in the third‐line setting: Real‐world data in an australian population
Author(s) -
Min Sandy Tun,
Roohullah Aflah,
Tognela Annette,
Jalali Azim,
Lee Margaret,
Wong Rachel,
Shapiro Jeremy,
Burge Matthew,
Yip Desmond,
Nott Louise,
Zimet Allan,
Lee Belinda,
Dean Andrew,
Steel Simone,
Wong HuiLi,
Gibbs Peter,
Lim Stephanie HuiSu
Publication year - 2022
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13553
Subject(s) - regorafenib , medicine , irinotecan , colorectal cancer , kras , oncology , population , oxaliplatin , cetuximab , cancer , performance status , surgery , environmental health
Background Colorectal cancer is the third most common cancer and second leading cause of cancer mortality in Australia, thus carrying a significant disease burden. Aims This analysis aims to explore real‐world treatment landscape of metastatic colorectal cancer in the third‐line setting. Methods We retrospectively analysed treatment of recurrent and advanced colorectal cancer (TRACC) registry database from 2009 onwards. Patients treated with palliative intent who progressed after two lines of therapies were included. One treatment line was defined as any combination of systemic therapy given until progression. Results Out of 1820 patients treated palliatively, 32% (590 patients) met study criteria. Of these, 43% (254 patients) proceeded to third‐line therapy, equating to 14% of all metastatic patients. In KRAS mutant or unknown tumours (97 patients), fluoropyrimidine (FP)‐oxaliplatin combination was the most common choice (51%), followed by FP‐irinotecan (15%), trifluridine/tipiracil (11%), mono‐chemotherapy (10%), regorafenib (5%) and others (7%). Majority of FP‐doublet (83%) was given as rechallenge. In 157 patients with KRAS wildtype disease, monotherapy with EGFR inhibitor was most commonly used (41%), followed by EGFR inhibitor with chemotherapy (20%), FP‐doublet (18%), mono‐chemotherapy (6%), trifluridine/tipiracil (6%), regorafenib (1%) and others (8%). Median overall survival was 7.1 months (range 0.4‐41.2), and median time on third‐line treatment was 3 months (range 0.1‐40). Conclusions In real‐world Australian population, treatment choices differed based on KRAS status and will likely change with the availability of newer drugs on the pharmaceutical benefits scheme. Survival outcomes are comparable to newer agents in clinical trials for select patients.